Lasa Supergenerics Ltd - 540702 - Compliance Under Regulation 23(9) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations. 2015
Pursuant to Regulation 23 [9] of the SEBI (Listing obligations and Disclosure Requirements), Regulations, 2015, please find enclosed herewith disclosure of related party transactions for the half year ended 30 September 2020 Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Attached is the copy of Press Release titled 'Lasa Receives further Injunction from Hon'ble High Court, Bombay restraining its competitor from Manufacturing albendazole in addition to other reliefs which is subject matter of patent infringement case, until disposal of suit' issued by the company Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Attached is a copy of Press Release tilted 'Lasa Supergenerics Receives Environmental Clearance for Benzimidazole Derivatives Capacity Expansion in Unit 2 Located at Khed'. Lasa Supergenerics Ltd - 540702 - HALF YEARLY CERTIFICATE FROM PRACTICING COMPANY SECRETARY UNDER REG 40(9)OF SEBI (LODR) REGULATIONS 2015.
Pursuant to Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing herewith the certificate from Amit R. Dadheech & Associates, Practicing Company Secretary for the half year ended September 30, 2020. Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Investor Presentation
LASA Supergenerics October 2020 Investor Presentation 2020-2021. Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lasa Supergenerics Reports Revenue of ? 109 Crores in H1 FY21 higher by 38% YoY Profit After Tax in Q2 FY21 grew by 31% on a QoQ basis to ? 7 Crores. Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q2 FY21 Earning call will be represented by Dr Omkar Herlekar Chairman & Managing Director on Date: Thursday, 29th October 2020 Time: 12.00 Noon (IST). Lasa Supergenerics Ltd - 540702 - Outcome Of Board Meeting Held Today I.E. October 26, 2020
Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today through video conferencing which was commenced at 11.30 a.m. and concluded at 01:30 p.m. have considered, approved and took on record the Unaudited Financial Results for the quarter and Half year ended September 30 2020. Lasa Supergenerics Ltd - 540702 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations,2015
This is to certify that in compliance with regulation 7(2) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, all activities in relation to share transfer facility are maintained by our Share Transfer Agent i.e. Bigshare Services Private Limited having permanent SEBI Registration No INR0000001385. Lasa Supergenerics Ltd - 540702 - Shareholding for the Period Ended September 30, 2020
Lasa Supergenerics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here